Related references
Note: Only part of the references are listed.Population Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors
Xiaofei Zhou et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2022)
WHO grading system for invasive pulmonary lung adenocarcinoma reveals distinct molecular signature: An analysis from the cancer genome atlas database
Fabien Forest et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2022)
Research progress of tumor targeted drug delivery based on PD-1/PD-L1
Dongzhu Liu et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2022)
Replication stress: from chromatin to immunity and beyond Yea-Lih Lin and Philippe Pasero
Yea-Lih Lin et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2021)
Discovery of AS-0141, a Potent and Selective Inhibitor of CDC7 Kinase for the Treatment of Solid Cancers
Takayuki Irie et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
MiR-200a with CDC7 as a direct target declines cell viability and promotes cell apoptosis in Wilm's tumor via Wnt/β-catenin signaling pathway
Xiu-Ling Liang et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2021)
Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer
Yuchen Guo et al.
GENOME MEDICINE (2021)
Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis
Fausto Petrelli et al.
IMMUNOTHERAPY (2021)
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial
Arndt Vogel et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)
Rac GTPase activating protein 1 promotes gallbladder cancer via binding DNA ligase 3 to reduce apoptosis
Rui Bian et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2021)
A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery
Kenichi Iwai et al.
SCIENCE ADVANCES (2021)
CDC7 kinase promotes MRE11 fork processing, modulating fork speed and chromosomal breakage
Michael D. Rainey et al.
EMBO REPORTS (2020)
New insights on sorafenib resistance in liver cancer with correlation of individualized therapy
Zhang Cheng et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2020)
Structural Basis for the Activation and Target Site Specificity of CDC7 Kinase
Samual D. Dick et al.
STRUCTURE (2020)
ATR Restrains DNA Synthesis and Mitotic Catastrophe in Response to CDC7 Inhibition
Michael D. Rainey et al.
CELL REPORTS (2020)
MicroRNA-29b targeting of cell division cycle 7-related protein kinase (CDC7) regulated vascular smooth muscle cell (VSMC) proliferation and migration
Qunhua Ma et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Overexpression of CDC7 in malignant salivary gland tumors correlates with tumor differentiation
Zohreh Jaafari-Ashkavandi et al.
BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY (2019)
Biochemical reconstitution of UV-induced mutational processes
Tomohiko Sugiyama et al.
NUCLEIC ACIDS RESEARCH (2019)
Post-Translational Modifications of the Mini-Chromosome Maintenance Proteins in DNA Replication
Zheng Li et al.
GENES (2019)
Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor
Kenichi Iwai et al.
SCIENCE ADVANCES (2019)
Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis
Alfredo Tartarone et al.
FUTURE ONCOLOGY (2019)
An ATR and CHK1 kinase signaling mechanism that limits origin firing during unperturbed DNA replication
Tatiana N. Moiseeva et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
A Dual Inhibitor of Cdc7/Cdk9 Potently Suppresses T Cell Activation
Elijah W. Chen et al.
FRONTIERS IN IMMUNOLOGY (2019)
Inducing and exploiting vulnerabilities for the treatment of liver cancer
Cun Wang et al.
NATURE (2019)
Targeting CDC7 sensitizes resistance melanoma cells to BRAFV600E-specific inhibitor by blocking the CDC7/MCM2-7 pathway
Shaimaa A. Gad et al.
SCIENTIFIC REPORTS (2019)
Targeting CDC7 improves sensitivity to chemotherapy of esophageal squamous cell carcinoma
Ji-Xiang Cao et al.
ONCOTARGETS AND THERAPY (2019)
Cdc7 activates replication checkpoint by phosphorylating the Chk1-binding domain of Claspin in human cells
Chi-Chun Yang et al.
ELIFE (2019)
A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy
Ronan P. McLaughlin et al.
BREAST CANCER RESEARCH (2019)
Serum Proteomic Signatures of Male Breast Cancer
Eleni Zografos et al.
CANCER GENOMICS & PROTEOMICS (2019)
Interleukin-1 receptor-associated kinase 1 correlates with metastasis and invasion in endometrial carcinoma
Yilin Wang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Cell division cycle 7 is a potential therapeutic target in oral squamous cell carcinoma and is regulated by E2F1
Shufang Jin et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2018)
CDC7-dependent transcriptional regulation of RAD54L is essential for tumorigenicity and radio-resistance of glioblastoma
Qi Li et al.
TRANSLATIONAL ONCOLOGY (2018)
Upregulation of BUB1B, CCNB1, CDC7, CDC20, and MCM3 in Tumor Tissues Predicted Worse Overall Survival and Disease-Free Survival in Hepatocellular Carcinoma Patients
Liping Zhuang et al.
BIOMED RESEARCH INTERNATIONAL (2018)
Nuclear PGK1 Alleviates ADP-Dependent Inhibition of CDC7 to Promote DNA Replication
Xinjian Li et al.
MOLECULAR CELL (2018)
Discovery of novel furanone derivatives as potent Cdc7 kinase inhibitors
Takayuki Irie et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
ATR kinase inhibition induces unscheduled origin firing through a Cdc7-dependent association between GINS and And-1
Tatiana Moiseeva et al.
NATURE COMMUNICATIONS (2017)
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Hiro Sato et al.
NATURE COMMUNICATIONS (2017)
p53 gain-of-function mutations increase Cdc7-dependent replication initiation
Arindam Datta et al.
EMBO REPORTS (2017)
Cell division cycle 7-kinase inhibitor PHA-767491 hydrochloride suppresses glioblastoma growth and invasiveness
Zubeyde Erbayraktar et al.
CANCER CELL INTERNATIONAL (2016)
Claspin recruits Cdc7 kinase for initiation of DNA replication in human cells
Chi-Chun Yang et al.
NATURE COMMUNICATIONS (2016)
Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint
Matthew T. Huggett et al.
ONCOTARGET (2016)
Regulation and roles of Cdc7 kinase under replication stress
Masayuki Yamada et al.
CELL CYCLE (2014)
DNA Replication and Oncogene-Induced Replicative Stress
Stephanie A. Hills et al.
CURRENT BIOLOGY (2014)
The Potent Cdc7-Dbf4 (DDK) Kinase Inhibitor XL413 Has Limited Activity in Many Cancer Cell Lines and Discovery of Potential New DDK Inhibitor Scaffolds
Nanda Kumar Sasi et al.
PLOS ONE (2014)
Discovery of XL413, a potent and selective CDC7 inhibitor
Elena S. Koltun et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
How do Cdc7 and cyclin-dependent kinases trigger the initiation of chromosome replication in eukaryotic cells?
Karim Labib
GENES & DEVELOPMENT (2010)
The DNA Damage Response: Making It Safe to Play with Knives
Alberto Ciccia et al.
MOLECULAR CELL (2010)
Share Paper
